We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Puretech Health Plc | LSE:PRTC | London | Ordinary Share | GB00BY2Z0H74 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -3.20 | -2.24% | 139.80 | 740,222 | 16:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 139.40 | 140.00 | 146.00 | 139.40 | 144.40 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Home Health Care Services | USD 65.12M | USD -65.7M | USD -0.2744 | -5.12 | 342.37M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 15:59:22 | AT | 158 | 139.80 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 09/1/2025 | 12:26 | ALNC |  PureTech receives FDA fast track designation for leukemia treatment |
| 09/1/2025 | 12:00 | UK RNS | PureTech Health PLC PRTC's LYT-200 Gets Fast Track Designation in AML |
| 08/1/2025 | 12:00 | UK RNS | PureTech Health PLC PureTech to Present at the JP Morgan Conference |
| 06/1/2025 | 07:00 | UK RNS | PureTech Health PLC PureTech Appoints UBS as UK Corporate Broker |
| 16/12/2024 | 14:35 | ALNC | IN BRIEF: PureTech Health says LYT-100 slows lung function decline |
| 16/12/2024 | 07:00 | UK RNS | PureTech Health PLC PRTC's Ph2b in IPF Successful; New SOC Potential |
| 11/12/2024 | 17:30 | UK RNS | PureTech Health PLC Holding(s) in Company |
| 11/12/2024 | 12:05 | UK RNS | PureTech Health PLC PRTC's Seaport Presents Ph1 SPT-300 Data at ACNP |
| 09/12/2024 | 07:00 | UK RNS | PureTech Health PLC PRTC Presents LYT-200 Phase 1b Data in AML at ASH |
| 04/12/2024 | 18:15 | ALNC | TOP NEWS: Retail pair and under-pressure Vistry booted out of FTSE 100 |
Puretech Health (PRTC) Share Charts1 Year Puretech Health Chart |
|
1 Month Puretech Health Chart |
Intraday Puretech Health Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 10/1/2025 | 15:49 | PureTech Health - innovative healthcare | 2,768 |
| 22/7/2018 | 20:35 | PureTech Health (PRTC) One to Watch Monday | - |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 15:59:22 | 139.80 | 158 | 220.88 | AT |
| 15:59:22 | 139.80 | 701 | 980.00 | AT |
| 15:59:22 | 139.80 | 399 | 557.80 | AT |
| 15:59:22 | 139.80 | 8 | 11.18 | AT |
| 15:59:09 | 139.69 | 1,424 | 1,989.14 | O |
| Top Posts |
|---|
Posted at 10/1/2025 08:20 by Puretech Health Daily Update Puretech Health Plc is listed in the Home Health Care Services sector of the London Stock Exchange with ticker PRTC. The last closing price for Puretech Health was 143p.Puretech Health currently has 239,421,312 shares in issue. The market capitalisation of Puretech Health is £342,372,476. Puretech Health has a price to earnings ratio (PE ratio) of -5.21. This morning PRTC shares opened at 144.40p |
Posted at 09/1/2025 16:43 by ohisay In the end you have to trust that what you liked in PRTC the other pharma companies like too .And that on the value you place on the assets they are more or less in agreement. It seems to me they are the only arbiters ..not the institutions or the brokers or you for that matter. For the most part the science decides this. So you just have to suck up the volatility of the daily trades if you are a believer. Which I am ! |
Posted at 07/1/2025 10:21 by takeiteasy So what does the firm need to do to turn the share price around having delivered pretty much on all fronts on the pharma product development side in terms of keeping to development timescales and quality outcomes.We seemingly have a majority of share holders who want to sell almost at any price regardless of all the recent positive news. We do not want the company sold at this silly price so that is a no no. I am not sure moving to a 100% US listing is the answer either. Perhaps they can only expedite the move to IPO vehicles with key assets that they have started. Use proceeds for more buy backs. Anyone any better ideas to send to the management....intere |
Posted at 17/12/2024 14:32 by salpara111 As someone who only bought in August at what appeared to be a bargain price of 160p I have to say that I have watched this in a somewhat bemused state as every share price rise on the back of a piece of good news is met immediately with a fall back.Ultimately the market will decide...if they were grossly undervalued they would be bought out by a larger predator....I've had two of my holdings acquired this year ((well its not a done deal yet for Direct Line!)so eventually one of two things will happen, either they will be acquired or Mr Market will decide that they are undervalued. I'm holding for at least another 6 months and will review at that point. |
Posted at 16/12/2024 14:43 by rambutan2 Am rather flummoxed re lack of share price reaction to trial results - conf call didnt sound anything but very positive, which is how i read them... |
Posted at 16/12/2024 09:43 by edwardt yes and i suspect citi are involved - hence their bizarre movements in stock. feels to me the share price is being played with - keep low to get fees on a raise... |
Posted at 30/10/2024 14:07 by takeiteasy Seaport announcements a master stroke in my book i.e. ensure a well over subscribed funding round and then follow up to the IIs with the message if you want more of the Seaport exposure without having to wait for the next funding round then buy some/more PRTC ... and heh presto PRTC price shoots up ..lols...:)nai etc |
Posted at 06/10/2024 03:54 by ohisay Liberum in their figurings late last year had LYT100 unrisked at 380m$.If my maths is correct that works out at £1.20p per share to PRTC . Given that theres nothing much in the current share price for that atm, one might reasonably expect an extra £1 per share in a success case. They say .. Depending on the outcome of the ELEVATE IPF Phase IIb trial, we believe that LYT-100 has >$1bn sales potential and LYT-100 would be attractive to a potential licensing partner, whether that be a company looking to enter the field or an existing player like Roche, who might see LYT-100 as an attractive means to extend its market position with a new potential backbone therapy |
Posted at 25/9/2024 06:53 by takeiteasy Bristol-Myers Squibb: Hold Rating Justified by Market-Reflected Approval of KarXT Despite Promising Clinical DataTipRanks Sep. 23, 2024, 05:15 AM BMO Capital analyst Evan Seigerman maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) today and set a price target of $48.00. Evan Seigerman has given his Hold rating due to a combination of factors, notably the anticipation that KarXT’s approval is already reflected in the current market price of Bristol-Myers Squibb’s shares. He acknowledges that while the approval of KarXT is expected given its strong clinical data, the actual impact on the stock will depend on the specifics of the drug’s label and the company’s ability to execute a successful launch. Seigerman also points out that a label without the black box warning typically associated with antipsychotics could provide a slight upside, but that this potential benefit appears to be accounted for in the stock’s valuation. hxxps://markets.busi So chaps, does our share price already reflect approval for Karxt? |
Posted at 25/7/2024 07:40 by ashkv At 167p - a market cap of GBP 400.64 million per Google Finance or at GBPUSD 1.29 Market Cap is US$516.8 million in dollar terms!!Net Cash of PRTC is US$ 473.3 million or nearly 92% of market cap (US$ 473.3mn/ US$516.8mn) equivalent to 153.2p!!! PRTC doesn't have any debt!!! NO VALUE TO UPCOMING ROYALTY STREAM OF US$400 million, other investments or drugs in development!!! GREAT TIME TO ANNOUNCE FURHTER BUYBACKS!!! Share price down nearly 1/3 since recent 250p tender offer!!! Nearly 50% upside at present levels to 250p recently concluded tender offer!!! |
Posted at 03/7/2024 14:17 by bahiflyer I'm amazed Invesco still have so many left. They've been drip feeding them down for the last 3 years or so it seems. Rather than buy backs, which did nothing for the share price last time, PRTC should open a dialogue with Invesco to find out what holding they'd be happy to stop selling at and either buy off them direct or find an alternative II to have an interest. That would be much easier to instigate if there was an actual dividend policy, which is after all the only long term way of returning money to shareholders directly, and that's what income funds want, which in turn would stimulate overall share price growth. It's something a decent PR team or advisers would point out to them |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
